CDK4/6 inhibitors have revolutionized the clinical treatment paradigm for HR+/HER2-advanced breast cancer by selectively inhibiting CDK4/6, restoring cell cycle control, and blocking tumor cell proliferation (Spring et al., 2020). Here, ERBB2 is linked to breast cancer.